The promise of a simple, disposable patch that a woman can apply at home, returning a breast-health assessment without a clinic visit, has long been a frontier in preventative medicine. For the team at Feminai, a Tel Aviv-based startup, that promise is now a tangible product in a box, backed by peer-reviewed data and a $10 million seed round. Their bet is that a lower-cost, non-invasive home screening workflow, prescribed by a clinician and reimbursed via a CPT code, can become a new standard of care for early detection [Feminai, 2026].
A clinical wedge into the home
Feminai's core product is the Feminai Breast Examination Kit, a wearable, disposable patch paired with AI software. The system is designed to analyze breast-tissue changes remotely, with the intent of identifying abnormalities that warrant further investigation [Feminai, 2026]. The company is not targeting direct-to-consumer sales. Instead, its go-to-market strategy hinges on providers, primarily virtual care clinics and other healthcare partners, who would prescribe the kit to patients. The long-term economic model relies on securing a dedicated CPT code for reimbursement, a common but rigorous path for novel diagnostics [Feminai, 2026].
This approach positions Feminai not as a replacement for mammography, but as a potential new layer in the screening continuum. The company is currently pursuing a De Novo classification request with the U.S. Food and Drug Administration, a regulatory pathway for novel devices with no predicate [FDA, 2026]. CEO Karny Ilan, a former general surgery resident at Sheba Medical Center, has stated a commercial launch is planned for year-end, supported by signed pilot programs with healthcare partners [Biomed 2026, 2026] [LinkedIn, 2026].
The data behind the device
For any new diagnostic tool, especially one intended for screening asymptomatic populations, clinical performance is the paramount metric. Feminai has published results from clinical trials conducted in the U.S. and Israel. A study published in Clinical Breast Cancer reported the system demonstrated 96% sensitivity and 82% specificity for distinguishing normal from abnormal findings, with a negative predictive value (NPV) of 98% [Clinical Breast Cancer, 2026]. These figures, particularly the high sensitivity and NPV, are crucial for a screening tool, as they indicate a low likelihood of missing a true cancer (sensitivity) and a high probability that a negative result is truly negative (NPV).
Early data from a preliminary trial at Sheba Medical Center also reported 96% detection accuracy [Technion LinkedIn post, Unknown]. While promising, these results represent early-stage validation. The real test will come with broader, real-world implementation and the scrutiny of the FDA's De Novo review process, which will independently evaluate the safety and effectiveness data.
The team and the $10 million backing
The company was founded in 2023 by a trio with complementary expertise: CEO Karny Ilan, MD, who brings the clinical perspective; CTO Shani Klein Antman, who leads the technical development; and CPO Gal Yanuka, who heads product and R&D [The Jerusalem Post, 2026]. This blend of medical, engineering, and product leadership is a typical blueprint for ambitious healthtech ventures.
Their vision attracted a $6 million seed round in January 2026, led by Vertex Ventures Israel with participation from ICI Fund, Fusion, Arben Ventures, Cactus Capital, and angel investor Mark Zitter [Preqin, Unknown]. This followed an earlier $4 million pre-seed round, bringing total disclosed funding to approximately $10 million [Calcalistech, 2026]. The company also received a 1.65 million NIS grant from the Israel Innovation Authority [Fusion VC blog, Unknown].
| Founder | Title | Background |
|---|---|---|
| Karny Ilan | CEO, Co-Founder | MD, Former General Surgery Resident, Sheba Medical Center [LinkedIn, 2026] |
| Shani Klein Antman | CTO, Co-Founder | Technical leadership in AI and engineering [The Jerusalem Post, 2026] |
| Gal Yanuka | CPO & Head of R&D, Co-Founder | Product and research & development leadership [LinkedIn, 2026] |
Navigating a crowded diagnostic landscape
Feminai enters a competitive field populated by established imaging giants and innovative startups. The path to adoption is fraught with specific, evidence-based challenges that the company must navigate.
- Regulatory and reimbursement gates. The FDA De Novo process is a significant milestone, but approval does not guarantee insurance coverage. Securing a CPT code and convincing payers of the test's clinical utility and cost-effectiveness is a separate, multi-year endeavor. The company's pilot programs are a first step in generating the real-world evidence needed for these conversations [Feminai, 2026].
- Clinical integration. Convincing busy providers to adopt and prescribe a novel home test requires demonstrating smooth integration into existing workflows and clear patient benefit. The partnership model with virtual care clinics is a logical entry point, as these organizations are often more agile in adopting new technologies.
- Competitive context. Feminai is not alone in seeking to improve breast cancer detection. Competitors range from companies like iSono Health, which is developing an automated 3D ultrasound system, to AI software firms like Subtle Medical that enhance existing imaging modalities, and large incumbents like Hologic and RadNet that continuously advance their own platforms [Public neutral summary]. Feminai's differentiation rests on the combination of a disposable hardware form factor and a remote screening workflow.
The company's most plausible answer to these challenges is its early clinical data and focused provider partnership strategy. By aiming to slot into a prescribed care pathway rather than selling directly to consumers, Feminai aligns itself with the existing medical ecosystem, which may ease adoption if the value proposition is proven.
The standard of care and what comes next
For the millions of women undergoing routine breast cancer screening, the current standard of care is mammography, often supplemented by ultrasound for those with dense breast tissue. This requires scheduling an appointment, traveling to a clinic, and undergoing a procedure that can be uncomfortable. Barriers like access, cost, and discomfort contribute to gaps in screening adherence. Feminai's proposition is to offer a convenient, accessible, and private alternative that could increase screening frequency and catch cancers earlier in populations that face these barriers.
The next twelve months are critical. The key milestones are clear: progress through the FDA's De Novo review, the initiation of its pilot programs with virtual care partners, and the planned commercial launch by year-end. Success on these fronts would not only validate Feminai's technical approach but also begin to answer the larger commercial question of whether the healthcare system is ready to prescribe and pay for remote breast screening at scale.
Sources
- [Biomed 2026, 2026] Daily Program - Biomed 2026 | https://kenes-exhibitions.com/biomed/daily-program/
- [Calcalistech, 2026] Feminai: Empowering women to conduct breast cancer screenings | https://www.calcalistech.com/
- [Clinical Breast Cancer, 2026] Study on Feminai's clinical trial results | https://www.clinicalbreastcancer.com/
- [FDA, 2026] FDA De Novo classification request | https://www.fda.gov/
- [Feminai, 2026] Feminai company website | https://www.feminai.com/
- [Fusion VC blog, Unknown] From ER Shifts to a $1.65M Healthtech Grant | https://blog.fusion-vc.com/p/from-er-shifts-to-a-165m-healthtech-feminai
- [LinkedIn, 2026] Gal Yanuka - Feminai profile | https://www.linkedin.com/in/gal-yanuka/
- [LinkedIn, 2026] Karny Ilan - Sheba Medical Center profile | https://il.linkedin.com/in/veredcohenherszaft
- [Preqin, Unknown] Feminai Ltd. Asset Profile | https://www.preqin.com/
- [Technion LinkedIn post, Unknown] Feminai healthtech/medtech post | https://www.linkedin.com/
- [The Jerusalem Post, 2026] Meet the women revolutionizing breast cancer detection | https://www.jpost.com/podcast/inside-israeli-innovation/article-811697